Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice

Cell Communication and Signaling

Volumn 10, Issue , 2012, Pages

  Höfig, Ines ^a   Ehrhardt, Harald ^a,b   Jeremias, Irmela ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FLUOROURACIL; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE CASPASE 8; ONCOGENE NFKBP65; ONCOGENE NOXA; ONCOGENE PUMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; RNA INTERFERENCE; SCHOOL CHILD; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

MUS;

EID: 84860813765     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-10-8     Document Type: Article

References (19)

1. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Sandberg R, Ernberg I, ProcNatlAcadSci USA 2005 102 2052 7 10.1073/pnas.0408105102 (Pubitemid 40262010)
2. Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Greshock J, Nathanson K, Martin AM, et al. Cancer Res 2007 67 3594 600 10.1158/0008-5472.CAN-06-3674 17440070 (Pubitemid 46762143)
3. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Peller S, Rotter V, Hum Mutat 2003 21 277 84 10.1002/humu.10190 12619113 (Pubitemid 36292969)
4. p53 and disease: when the guardian angel fails. Royds JA, Iacopetta B, Cell Death Differ 2006 13 1017 26 10.1038/sj.cdd.4401913 16557268
5. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A, Mathe E, Kato S, et al. Hum Mutat 2007 28 622 9 10.1002/humu.20495 17311302 (Pubitemid 46744292)
6. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Brauer KM, Werth D, von Schwarzenberg K, et al. Cancer Res 2007 67 5489 97 10.1158/0008-5472.CAN-07-0302 17545631 (Pubitemid 46997290)
7. Targeting of gene expression by siRNA in CML primary cells. Merkerova M, Klamova H, Brdicka R, et al. MolBiol Rep 2007 34 27 33 (Pubitemid 46220354)
8. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Seiffert M, Stilgenbauer S, Doehner H, et al. Leukemia 2007 21 1977 83 10.1038/sj.leu.2404863 17637809 (Pubitemid 47299973)
9. Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. Gershan JA, Johnson BD, Weber J, et al. Genet Vaccines 2005 3 4 10.1186/1479-0556-3-4 (Pubitemid 41522133)
10. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease. Lock RB, Liem NL, Papa RA, Methods Mol Med 2005 111 323 34 15911988
11. Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Borgmann A, Baldy C, von Stackelberg A, et al. PediatrHematolOncol 2000 17 635 50
12. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Schmitz M, Breithaupt P, Scheidegger N, et al. Blood 2011 118 1854 64 10.1182/blood-2010-11-320309 21670474
13. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Ehrhardt H, Hacker S, Wittmann S, et al. Oncogene 2008 27 783 93 10.1038/sj.onc.1210666 17637740 (Pubitemid 351186307)
14. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Baader E, Toloczko A, Fuchs U, et al. Cancer Res 2005 65 7888 95 16140959 (Pubitemid 41297266)
15. TRAIL-induced survival and proliferation in cancer cells resistant towards TRAIL-induced cell death mediated by NFB. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I, Oncogene 2003 22 3842 52 10.1038/sj.onc.1206520 12813457 (Pubitemid 36819657)
16. Optimized anti-tumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Ehrhardt H, Schrembs D, Moritz C, et al. Blood doi:10.1182/blood-2010-02-269811
17. Humanized mice in translational biomedical research. Shultz LD, Ishikawa F, Greiner DL, Nat Rev Immunol 2007 7 118 30 10.1038/nri2017 17259968 (Pubitemid 46174859)
18. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Kamel-Reid S, Letarte M, Sirard C, et al. Science 1989 246 1597 600 10.1126/science.2595371 2595371 (Pubitemid 20036692)
19. The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Lock RB, Liem N, Farnsworth ML, et al. Blood 2002 99 4100 8 10.1182/blood.V99.11.4100 12010813 (Pubitemid 35332053)